Introduction
According to the World Health 
Genomic Structure of HCV
The genome of the hepatitis C virus consists of one 9.6 kb single- 
Newer anti-HCV drugs
In the last few years, numerous 
* The combination of ledipasvir (LDV) and sofosbuvir (SOF) is available as a single tablet fixed-dose combination (Harvoni®, Gilead Sciences). The tablet contains the NS5B polymerase inhibitor SOF (400 mg) and the NS5A inhibitor ledipasvir (LDV, 90 mg).

Treatment of HCV genotypes 4, 5, and 6
Treatment concepts for GT1 are generally valid for GT4-6. Most of the new DAAs are also effective against GT4-6. Thus, dual therapy with PEG-IFN and RBV can be avoided if possible.
Triple therapy of SOF + PEG-IFN/RBV
for 12 weeks has resulted in 96-100 % SVR in GT4-6 patients [25] . However, the number of patients was low (n=35) 
New hope for specific groups
More recognition of sub genomic and genomic replication systems of different virus genotypes lead to major advances in the virus molecular BMC Infect Dis;13: 288.
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